Abstract: Objective To evaluate the clinical efficacy and safety of emitasvir phosphate combined with sofosbuvir in the treatment of patients with genotype 1 non-cirrhotic chronic hepatitis C virus (HCV) infection. Methods A total of 81 patients with genotype 1 non-cirrhotic chronic HCV infection who were initially treated in Mianyang Central Hospital from January 2024 to December 2024 were selected as the study subjects and were treated with emitasvir phosphate combined with sofosbuvir for 12 weeks. The sustained virological response at 12 weeks (SVR12) after the end of treatment, rapid virological response at 4 weeks after treatment, virological response at 12 weeks after treatment and the occurrence of adverse reactions were observed. Results Most of the 81 patients with genotype 1 non-cirrhotic chronic HCV infection who were initially treated were middle-aged and elderly married men (46 cases, 56.8%), mostly from rural areas with low economic development level (67 cases, 82.7%). HCV infection was mainly transmitted through blood contact (69 cases, 85.2%), and the most common HCV genotype was genotype 1b (78 cases, 96.3%). All patients completed the 12-week combination regimen of emitasvir phosphate plus sofosbuvir, with a 4-week rapid virologic response rate of 96.3% (78/81) and a 100% (81/81) virologic response rate at 12 weeks after treatment. The SVR12 after the end of treatment was 100% (81/81). There were no serious adverse reactions during the treatment period, but 13 patients had mild adverse reactions. Conclusion The 12-week regimen of emitasvir phosphate combined with sofosbuvir has good efficacy and safety, and can be used as an effective treatment for patients with genotype 1 non-cirrhotic chronic HCV infection, which is worthy of further clinical application.

Key words: Hepatitis C virus, Emitasvir phosphate, Sofosbuvir, Genotype 1, Real-world study